FDA Fast-Tracks RSV Vaccine for Kids with Special Voucher
Published Date: 4/16/2026
Notice
Summary
The FDA just gave a big thumbs-up to AREXVY, a vaccine that helps protect kids from a serious lung virus called RSV. This approval used a special Rare Pediatric Disease Priority Review Voucher, which speeds up the review process for important medicines for rare childhood diseases. This means faster access to life-saving treatments without extra costs, making a real difference for families and healthcare providers.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA OKs AREXVY RSV Vaccine
You may now have an FDA-approved Respiratory Syncytial Virus (RSV) vaccine called AREXVY. The FDA announced on April 16, 2026 that AREXVY (BLA supplement approved June 7, 2024) meets the criteria for redeeming a Rare Pediatric Disease Priority Review Voucher.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in